CureImmune Pipeline

We leverage our deep understanding of the immunobiology involved in cancer and other diseases when looking for target(s) of our therapeutic intervention. Using monoclonal antibody and bispecific antibody platforms, we are developing several therapeutic agents in our current pipeline for oncology. A bispecific / bifunctional agent is a single molecular entity that engages two different targets, which will have additive or synergistic effects to exert optimum therapeutic efficacy.

CIT-801 (Bifunctional Antibody)
CIT-802 (Bifunctional Protein)
CIT-110 (Antagonist Antibody)
CIT-700 (Agonist Antibody)
CIT-210 (Antagonist Antibody)